» Articles » PMID: 37446881

The Anti-Arthritic Activity of Diclofenac Lipid-Core Nanocapsules: Stereological Analysis Showing More Protection of Deep Joint Components

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Jul 14
PMID 37446881
Authors
Affiliations
Soon will be listed here.
Abstract

Diclofenac is the most prescribed nonsteroidal anti-inflammatory drug worldwide and is used to relieve pain and inflammation in inflammatory arthritis. Diclofenac is associated with serious adverse effects, even in regular-dose regimens. Drug delivery systems can overcome this issue by reducing adverse effects and optimizing their efficacy. This study evaluated the activity of lipid-core nanocapsules loaded with diclofenac (DIC-LNCs) in an experimental model of adjuvant-induced arthritis. The diclofenac nanoformulation was obtained via self-assembly. A stereological analysis approach was applied for the morphological quantification of the volume, density, and cellular profile count of the metatarsophalangeal joints of rats. Proinflammatory cytokines and biochemical profiles were also obtained. Our results showed that the diclofenac nanocapsule DIC-LNCs were able to reduce arthritis compared with the control group and the DIC group. DIC-LNCs efficiently reduced proinflammatory cytokines, C-reactive protein, and xanthine oxidase levels. Additionally, DIC-LNCs reduced the loss of synoviocytes and chondrocytes compared with the DIC ( < 0.05) and control groups ( < 0.05). These data suggest that DIC-LNCs have anti-arthritic activity and preserve joint components, making them promising for clinical use.

References
1.
van Walsem A, Pandhi S, Nixon R, Guyot P, Karabis A, Moore R . Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015; 17:66. PMC: 4411793. DOI: 10.1186/s13075-015-0554-0. View

2.
McInnes I, Schett G . Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7(6):429-42. DOI: 10.1038/nri2094. View

3.
Cruz L, Schaffazick S, Dalla Costa T, Soares L, Mezzalira G, P da Silveira N . Physico-chemical characterization and in vivo evaluation of indomethacin ethyl ester-loaded nanocapsules by PCS, TEM, SAXS, interfacial alkaline hydrolysis and antiedematogenic activity. J Nanosci Nanotechnol. 2006; 6(9-10):3154-62. DOI: 10.1166/jnn.2006.417. View

4.
Bulcao R, de Freitas F, Dallegrave E, Venturini C, Baierle M, Durgante J . In vivo toxicological evaluation of polymeric nanocapsules after intradermal administration. Eur J Pharm Biopharm. 2013; 86(2):167-77. DOI: 10.1016/j.ejpb.2013.04.001. View

5.
Boechat A, de Oliveira C, Tarrago A, Costa A, Malheiro A, Guterres S . Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model. Int J Nanomedicine. 2015; 10:6603-14. PMC: 4622525. DOI: 10.2147/IJN.S85369. View